Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study

EGL-003, a selective IL-2 agonist,…

Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers

Egle Therapeutics SAS (Egle), an…